Dexmedetomidine Attenuates LPS-Stimulated Alveolar Type II Cells' Injury through Upregulation of miR-140-3p and Partial Suppression of PD-L1 Involving Inactivating JNK-Bnip3 Pathway

Dexmedetomidine (DEX), which is reported to be a newly discovered, novel α-2 adrenoceptor agonist, is known to exhibit anti-inflammatory properties in several diseases. DEX regulates inflammation-related signaling pathways and genes through interactions with several miRNAs. This study verified that...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xianfeng, Hu, Juntao, Lai, Jie, Zhang, Zhiyong, Tang, Zhanhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357803/
https://www.ncbi.nlm.nih.gov/pubmed/35958433
http://dx.doi.org/10.1155/2022/8433960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357803/
https://www.ncbi.nlm.nih.gov/pubmed/35958433
http://dx.doi.org/10.1155/2022/8433960

Ejemplares similares